Summary
72 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 24 EUR is left as net profit.
- It holds more cash than debt: 127.0M € against 107.7M €.
- It earns 15 EUR a year on every 100 EUR of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 3.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.9 EUR for 1 EUR of yearly profit. Over the last five years it was 20.3 EUR on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it fell by 3.1% a year. For the next fiscal year analysts expect revenue to grow by 4.1%. Earnings per share fell by 9.7% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 36 EUR
- Research and development 7.0 EUR
- Sales and administration 35 EUR
- Taxes and other -2.0 EUR
- Net profit 24 EUR
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 EUR
Out of every 100 EUR of revenue, 24 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.67%
- Paid out of profit
- 26%
You receive 0.96 € per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail